# Result Update

19<sup>th</sup> Jan 2022

# L&T Technologies Ltd (LTTS)

**IT Services** 



17.34

## Results Slightly Below Estimates; Outlook Continues to be Strong

L&T Technologies (LTTS) reported a healthy set of results in Q3FY22. Its revenue stood at Rs 1,688 Cr, registering a growth of 5% QoQ, slightly below our expectations. Operating profit exhibited robust growth of 6.1% QoQ to Rs 213 Cr. However, the company's operating margins contracted by 320bps QoQ to 15.2%, primarily because of the extended wage hike along with higher operating and employee expenses. The management is confident of achieving sustainable operating margins moving forward as it factors in the strong cost optimization effort undertaken by the company as well as its strong execution capabilities. Net income for Q3FY22 stood at Rs 186 Cr, improving by 8.2% QoQ. The management has also retained its revenue guidance to 19%-20%. The company's deal pipeline continues to remain strong vis-à-vis the previous quarter as it signed three large deals including two \$10 Mn+ deals. Digital and leading-edge technologies contributed 56% of the revenues during the quarter. The management is confident of gaining further momentum from the next quarter onwards on account of a healthy deal pipeline and ram up in the new deal wins.

We recommend a BUY rating on the stock and assign a 40x P/E multiple to its FY24E earnings of Rs 148/share to arrive at a TP of Rs 5,960/share, implying an upside potential of 10% from CMP.

# Strong broad-based performance

On the vertical front, the Transportation vertical grew by 5.1% QoQ, the Industrial products vertical by 0.7% QoQ, Plant Engineering by 4.4% QoQ and Medical Devices by 1.5% QoQ. Telecom and Hi-Tech reported growth of 4.7% QoQ and the majority of the verticals are expected to witness a strong recovery moving forward. They are likely to report healthy growth from the next quarter onwards owing to the strong deal pipeline.

On the geographical front, North America (62% of revenue) improved by 2.8 % QoQ, Europe (149 by 2.3% QoQ, India business grew by 9.3% QoQ while the ROW improved by 3% QoQ.

#### **Outlook & Valuation**

LTTS has built a robust business model and its several long-term contracts spread across verticals will help the company generate sustainable growth in the upcoming quarters. With depreciation in INR, lower travel cost, and strong execution capabilities, EBITDA margins, too, are likely to expand in the near term.

We recommend a BUY and assign 40x P/E multiple to its FY24E earnings of Rs 148 per share, which gives a TP of Rs 5,960/share, implying an upside potential of 10% from CMP.

## Key Financials (Consolidated)

| (Rs Cr)       | FY21  | FY22  | FY23  | FY24E |
|---------------|-------|-------|-------|-------|
| Net Sales     | 5,450 | 6,354 | 7,433 | 8,786 |
| EBIDTA        | 1,007 | 1,197 | 1,496 | 1,779 |
| Net Profit    | 667   | 1,047 | 1,294 | 1,551 |
| EPS (Rs)      | 63.7  | 100.0 | 123.6 | 148.1 |
| PER (x)       | 43.9  | 51.2  | 41.4  | 34.6  |
| EV/EBIDTA (x) | 28    | 43    | 34    | 28    |
| P/BV (x)      | 9     | 13    | 11    | 9     |
| ROE (%)       | 21%   | 27%   | 27%   | 27%   |

Source: Company, Axis Research

|                            | (CMP as of Jan 18, 2022) |
|----------------------------|--------------------------|
| CMP (Rs)                   | 5,421                    |
| Upside /(Downside (%))     | 10%                      |
| High/Low (Rs)              | 5,963/4,879              |
| Market cap (Cr)            | Rs 57,188                |
| Avg. daily vol. (6m) Shrs. | 1,12,803                 |

#### Shareholding (%)

No. of shares (Cr)

|             | Jun-21 | Sept-21 | Dec-21 |
|-------------|--------|---------|--------|
| Promoter    | 74.2   | 74.2    | 73.9   |
| FIIs        | 8.9    | 9.5     | 9.2    |
| MFs / UTI   | 6.0    | 5.5     | 4.8    |
| Banks / Fls | 0.2    | 0.2     | 0.2    |
| Others      | 10.7   | 10.6    | 11.9   |

#### Financial & Valuations

| Y/E Mar (Rs Cr) | FY22E | FY23E | FY24E |
|-----------------|-------|-------|-------|
| Net Sales       | 6,354 | 7,433 | 8,786 |
| EBITDA          | 1,197 | 1,496 | 1,779 |
| Net Profit      | 1,047 | 1,294 | 1,551 |
| EPS (Rs)        | 100.0 | 123.6 | 148.1 |
| PER (x)         | 51.2  | 41.4  | 34.6  |
| EV/EBITDA (x)   | 43    | 34    | 28    |
| P/BV (x)        | 13    | 11    | 9     |
| RoE (%)         | 27%   | 27%   | 27%   |


#### **ESG disclosure Score\*\***

| Environmental Disclosure    | NA |
|-----------------------------|----|
| Social Disclosure Score     | NA |
| Governance Disclosure Score | NA |
| Total ESG Disclosure Score  | NA |

Source: Bloomberg, Scale: 0.1-100

\*\*Note: This score measures the amount of ESG data a company reports publicly, and does not measure the company's performance on any data point. All scores are based on 2020 disclosures.

#### Relative performance



Source: Capitaline, Axis Securities

# Omkar Tanksale

Research Analyst

Call: (022) 4267 1759, 9819327371 email: Omkar.tanksale@axissecurities.in



# Key Concall takeaways

- 1) Three large deal wins: The company reported three large deal wins with TCV of \$10 Mn in the quarter. The deal pipeline continues to be strong a trend similar to that of peers.
- 2) **Maintains PAT margin at 14-15%:** The company plans to invest in sales, localization, re-skilling, and post-Covid workspaces. Moreover, it has extended wage hikes in H2FY22 and its impact is expected to be 150-200bps. The management has maintained its PAT margin band of 14-15%.
- 3) Good traction in digital engineering: The management sees good traction in digital engineering and six of its big bets viz Electric Autonomous & Connected Vehicle (EACV), 5G, Med-tech, AI & Digital Products, Digital Manufacturing and Sustainability.

# Revenue by Service offering: Segment Revenue

|                     | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|---------------------|--------|--------|--------|--------|--------|--------|
| Transportation      | 413    | 426    | 449    | 474    | 504    | 537    |
| Plant Engineering   | 189    | 206    | 224    | 237    | 246    | 261    |
| Industrial Products | 257    | 271    | 272    | 296    | 322    | 329    |
| Medical Devices     | 175    | 178    | 177    | 177    | 195    | 201    |
| Telecom & Hi-tech   | 280    | 321    | 318    | 335    | 340    | 360    |
| Total               | 1,314  | 1,401  | 1,441  | 1,518  | 1,608  | 1,688  |

Source: Company, Axis Research

## **Segment Results**

| No of Active clients | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|----------------------|--------|--------|--------|--------|--------|--------|
| Transportation       | 64     | 70     | 75     | 92     | 99     | 98     |
| Plant Engineering    | 36     | 49     | 52     | 60     | 55     | 66     |
| Industrial Products  | 65     | 77     | 78     | 86     | 99     | 96     |
| Medical Devices      | 52     | 56     | 56     | 58     | 64     | 65     |
| Telecom & Hi-tech    | 32     | 37     | 37     | 41     | 43     | 48     |
| Total                | 249    | 289    | 298    | 336    | 359    | 373    |

Source: Company, Axis Research

# Revenue by vertical

|                     | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|---------------------|--------|--------|--------|--------|--------|--------|
| Transportation      | 31%    | 30%    | 31%    | 31%    | 31%    | 32%    |
| Plant Engineering   | 14%    | 19%    | 19%    | 20%    | 20%    | 15%    |
| Industrial Products | 20%    | 23%    | 22%    | 22%    | 21%    | 20%    |
| Medical Devices     | 13%    | 15%    | 16%    | 16%    | 15%    | 12%    |
| Telecom & Hi-tech   | 21%    | 13%    | 12%    | 12%    | 12%    | 21%    |

Source: Company, Axis Research



# Revenue by Geography

|               | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|---------------|--------|--------|--------|--------|--------|--------|
| North America | 60%    | 61%    | 62%    | 62%    | 63%    | 63%    |
| Europe        | 16%    | 16%    | 17%    | 17%    | 17%    | 17%    |
| India         | 14%    | 14%    | 13%    | 13%    | 13%    | 14%    |
| Rest of World | 10%    | 9%     | 9%     | 8%     | 7%     | 7%     |
| Total         | 100%   | 100%   | 100%   | 100%   | 100%   | 100%   |

Source: Company, Axis Research

# Revenue Mix

|          | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|----------|--------|--------|--------|--------|--------|--------|
| Onsite   | 45%    | 43%    | 42%    | 42%    | 42%    | 41%    |
| Offshore | 55%    | 57%    | 58%    | 58%    | 58%    | 59%    |
| Total    | 100%   | 100%   | 100%   | 100%   | 100%   | 100%   |

Source: Company, Axis Research

## **Client Profile**

|                          | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|--------------------------|--------|--------|--------|--------|--------|--------|
| Number of Active clients | 283    | 296    | 306    | 305    | 314    | 318    |
|                          |        |        |        |        |        |        |
| 50 Mn +                  | 0      | 0      | 0      | 0      | 0      | 0      |
| 30 Mn+                   | 1      | 1      | 0      | 0      | 1      | 2      |
| 20 Mn +                  | 5      | 4      | 3      | 5      | 6      | 6      |
| 10 Mn+                   | 20     | 18     | 20     | 20     | 21     | 22     |
| 5 Mn +                   | 44     | 41     | 39     | 43     | 45     | 44     |
| 1mn +                    | 116    | 118    | 122    | 122    | 125    | 126    |

Source: Company, Axis Research

# **Client Contribution to revenue**

|                 | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|-----------------|--------|--------|--------|--------|--------|--------|
| Top 5           | 17%    | 16%    | 16%    | 16%    | 17%    | 17%    |
| Top 10          | 28%    | 27%    | 27%    | 27%    | 27%    | 29%    |
| Top 20          | 45%    | 44%    | 44%    | 44%    | 44%    | 44%    |
|                 |        |        |        |        |        |        |
| Utilization (%) | 75%    | 78%    | 79%    | 79%    | 78%    | 76%    |

Source: Company, Axis Research

# **Employee Data**

|                  | Q2FY21 | Q3FY21 | Q4FY21 | Q1FY22 | Q2FY22 | Q3FY22 |
|------------------|--------|--------|--------|--------|--------|--------|
| Bilable hadcount | 14,778 | 14,975 | 15,335 | 15,896 | 16,875 | 18,975 |
| Sales & Support  | 1,124  | 1,094  | 1,117  | 1,076  | 1,108  | 1,143  |
| Total            | 15,902 | 16,069 | 16,452 | 16,972 | 17,983 | 20,118 |
|                  |        |        |        |        |        |        |
| Attrition (%)    | 11%    | 11%    | 11%    | 15%    | 17%    | 18%    |


Source: Company, Axis Research




# Valuation and Outlook

We believe LTTS will deliver long-term sustainable growth aided by a healthy deal pipeline and strong execution. We recommend a BUY and assign 40x P/E multiple to its FY24E earnings of Rs 148 per share, which gives a TP of Rs 5,960/share, implying an upside potential of 10% from CMP.

## LTTS 12M Fwd PE Band



LTTS 1Y Fwd PE Chart





Result Update (Rs Cr)

| Y/E March                            | Q3FY22 | Q2FY21 | Q3FY21 | % change<br>(YoY) | % change<br>(QoQ) |
|--------------------------------------|--------|--------|--------|-------------------|-------------------|
| Total Revenue                        | 1,688  | 1,608  | 1,401  | 20%               | 5%                |
| Direct cost                          | 1,688  | 1,401  | 1,401  |                   |                   |
| Gross Profit                         | 922    | 856    | 856    | 8%                | 8%                |
| SG & Other expenses                  | 398    | 355    | 270    | 48%               | 12%               |
| EBITDA                               | 1,081  | 1,258  | 1,258  | -14%              | -14%              |
| EBITDA margin                        | 233    | 349    | 349    |                   | 0%                |
| Depreciation                         | 18%    | 22%    | 22%    | (401)             | (401)             |
| Operating Income                     | 37     | 29     | 49     |                   |                   |
| Margin(%)                            | 11     | 11     | 11     |                   |                   |
| Total Other Income/(Expense)         | 53     | 53     | 62     |                   |                   |
| Income Before Income Taxes           | 340    | 314    | 251    | 36%               | 8%                |
| Total Taxes                          | 17%    | 20%    | 20%    | (237)             | (237)             |
| ETR (%)                              | 0      | 0      | 0      |                   |                   |
| Net Profit After Taxes               | 340    | 314    | 251    | 36%               | 8%                |
|                                      | 91     | 84     | 64     |                   |                   |
| Net Income After Extraordinary Items | 16%    | 18%    | 18%    | (200)             | (200)             |
| Margin(%)                            | 250    | 231    | 187    | 34%               | 8%                |
|                                      | -      | -      | -      |                   |                   |
| EPS                                  | 23.61  | 21.89  | 17.75  | 33%               | 8%                |



# Financials (Consolidated)

# Profit & Loss (Rs Cr)

| Y/E March   | FY21    | FY22E   | FY23E   | FY24E   |
|---|---------|---------|---------|---------|
| Net sales   | 5,450   | 6,354   | 7,433   | 8,786   |
| Other operating income                            | 0       | 0       | 0       | 0       |
| Total income                                      | 5,450   | 6,354   | 7,433   | 8,786   |
| Change in continent consideration on acquisitions | -       | -       | -       | -       |
| Employee benefit Expenses                         | 3,355.0 | 3,752.6 | 4,561.3 | 5,381.6 |
| Other Expenses                                    | 1,087.3 | 1,405.0 | 1,375.1 | 1,625.5 |
| EBITDA  | 1,007   | 1,197   | 1,496   | 1,779   |
| Other income                                      | 154     | 144     | 149     | 176     |
| PBIDT   | 1,161   | 1,341   | 1,645   | 1,955   |
| Depreciation                                      | 218     | 182     | 82      | 82      |
| Interest & Fin Chg.                               | 46      | 34      | 2       | 2       |
| E/o income / (Expense)                            | 0       | 0       | 0       | 0       |
| Pre-tax profit                                    | 897     | 1,126   | 1,562   | 1,872   |
| Tax provision                                     | 231     | 79      | 268     | 321     |
| (-) Minority Interests                            | 0       | 0       | 0       | 0       |
| Associates  | 0       | 0       | 0       | 0       |
| Profit after Tax                                  | 667     | 1,047   | 1,294   | 1,551   |
| Other Comprehensive Income                        | 0.0     | 0.0     | 0.0     | 0.0     |
| PAT after Comprehensive Income                    | 667     | 1,047   | 1,294   | 1,551   |

Source: Company, Axis Securities

Balance Sheet (Rs Cr)

| Y/E March             | FY21    | FY22E   | FY23E   | FY24E   |
|-----------------------|---------|---------|---------|---------|
| Total assets          | 3,832   | 4,630   | 5,539   | 6,349   |
| Net Block             | 135.3   | 103.6   | 171.9   | 240.1   |
| CWIP                  | 15.0    | 15.0    | 15.0    | 15.0    |
| Investments           | 915.4   | 915.4   | 915.4   | 915.4   |
| Wkg. cap. (excl cash) | 1,372   | 1,286   | 1,228   | 1,464   |
| Cash / Bank balance   | 1,395.5 | 2,311.3 | 3,210.1 | 3,715.6 |
| Misc. Assets          | (1.0)   | (1.0)   | (1.0)   | (1.0)   |
| Capital employed      | 3,832   | 4,630   | 5,539   | 6,349   |
| Equity capital        | 20.9    | 20.9    | 20.9    | 20.9    |
| Reserves              | 3,311   | 4,052   | 4,967   | 6,064   |
| Minority Interests    | 6.9     | 6.9     | 6.9     | 6.9     |
| Borrowings            | 491     | 493     | 495     | 497     |
| Def tax Liabilities   | 0.0     | 0.0     | 0.0     | 0.0     |



Cash Flow (Rs Cr)

| Y/E March               | FY21    | FY22E  | FY23E  | FY24E |
|-------------------------|---------|--------|--------|-------|
| Sources                 | 783     | 925    | 999    | 1,181 |
| Cash profit             | 930     | 1,262  | 1,377  | 1,634 |
| (-) Dividends           | 195     | 306    | 379    | 454   |
| Retained earnings       | 735     | 956    | 999    | 1,180 |
| Issue of equity         | 0.0     | 0.0    | 0.0    | 0.0   |
| Change in Oth. Reserves | 91.0    | 0.0    | 0.0    | 0.0   |
| Borrowings              | 2       | 2      | 2      | 2     |
| Others                  | -46     | -34    | -2     | -2    |
| Applications            | 783     | 925    | 999    | 1,181 |
| Capital expenditure     | (113.5) | 95.0   | 158.6  | 439.0 |
| Investments             | 0.0     | 0.0    | 0.0    | 0.0   |
| Net current assets      | (281.3) | (86.3) | (58.1) | 236.2 |
| Change in cash          | 1,177.6 | 915.8  | 898.8  | 505.5 |
| Closing cash            | 1,395   | 1,395  | 1,395  | 1,395 |
|                         |         |        |        |       |


Source: Company, Axis Securities

Ratio Analysis (%)

| Y/E March                   | FY21    | FY22E   | FY23E | FY24E |
|-----------------------------|---------|---------|-------|-------|
| Sales growth                | (3.0)   | 16.6    | 17.0  | 18.2  |
|                             |         |         |       |       |
| OPM                         | 18.5    | 18.8    | 20.1  | 20.2  |
| Oper. profit growth         | (9.3)   | 18.8    | 25.0  | 18.9  |
| COGS / Net sales            | 0.0     | 0.0     | 0.0   | 0.0   |
| Overheads/Net sales         | 20.0    | 22.1    | 18.5  | 18.5  |
| Depreciation / G. block     | (292.6) | (572.7) | 119.7 | 119.7 |
| Effective interest rate (%) | 9.2     | 6.8     | 0.3   | 0.3   |
|                             |         |         |       |       |
| Net wkg.cap / Net sales     | 0.31    | 0.24    | 0.19  | 0.17  |
| Net sales / Gr block (x)    | 10.3    | 9.3     | 8.9   | 9.0   |
|                             |         |         |       |       |
| RoCE                        | 27%     | 28%     | 31%   | 31%   |
| Debt / equity (x)           | 0.10    | 0.08    | 0.07  | 0.06  |
| Effective tax rate          | 25.7    | 7.0     | 17.1  | 17.2  |
| RoE                         | 21%     | 27%     | 27%   | 27%   |
| Payout ratio (Div/NP)       | 25.0    | 25.0    | 25.0  | 25.0  |
|                             |         |         |       |       |
| EPS (Rs.)                   | 63.7    | 100.0   | 123.6 | 148.1 |
| EPS Growth                  | (18.1)  | 57.1    | 23.6  | 19.8  |
| CEPS (Rs.)                  | 84.5    | 117.4   | 131.4 | 155.9 |
| DPS (Rs.)                   | 15.9    | 25.0    | 30.9  | 37.0  |



# **\_&T Technology Services Price Chart and Recommendation History**



| Date      | Reco | TP    | Research            |
|-----------|------|-------|---------------------|
| 08-Mar-21 | BUY  | 3,200 | Initiating Coverage |
| 04-May-21 | BUY  | 3,190 | Result Update       |
| 14-Jul-21 | BUY  | 3,215 | Result Update       |
| 03-Sep-21 | HOLD | 4,290 | Event Update        |
| 20-Oct-21 | BUY  | 5,790 | Result Update       |
| 19-Jan-22 | BUY  | 5,960 | Result Update       |
|           |      |       |                     |



#### About the analyst



Omkar Tanksale

Research Analyst

omkar.tanksale@axissecurities.in

Call: (022) 4267 1737

#### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

- 1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
- 2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
- 3. ASL has no material adverse disciplinary history as on the date of publication of this report.
- 4. I/We, Omkar Tanksale, MBA-Finance, author/s and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, etc. in the subject company in the last 12-month period. Any holding in stock No
- 5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
- 6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or:

Managed or co-managed public offering of the securities from the subject company of this research report and / or;

Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

#### Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.



| DEFINITION OF RATINGS |  |  |  |  |
|-----------------------|--|--|--|--|
| Ratings               | Expected absolute returns over 12-18 months  |  |  |  |
| BUY                   | More than 10%  |  |  |  |
| HOLD                  | Between 10% and -10%   |  |  |  |
| SELL                  | Less than -10%   |  |  |  |
| NOT RATED             | We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation |  |  |  |
| UNDER REVIEW          | We will revisit our recommendation, valuation and estimates on the stock following recent events           |  |  |  |
| NO STANCE             | We do not have any forward looking estimates, valuation or recommendation for the stock                    |  |  |  |

#### Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advice necessarily and the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

#### Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, Dealing office: 1st Floor, I-Rise Building, Q Parc, Loma Park, Thane, Ghansoli, Navi Mumbai-400701, Regd. off.- Axis House,8th Floor, Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: Anand Shaha, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706